Several new nonpeptide ARBs are undergoing clinical trials or are at pre-clinical stages of development. Among these are embusartan (BAY 10-6734 or BAY 10-6734), KRH-594, fonsartan (HR 720) and pratosartan (KT3-671). Pratosartan, for example, has a novel structure: a seven-membered ring that bears an oxo moiety (C=O) fused to the imidazole ring (figure 4), and its affinity for the AT receptor is about 7 times higher than  losartan's. The purpose of the oxo group is similar to that of the carboxylic acid groups on other ARBs.<br />
Other attributes of ARBs are also under investigation, such as the positive effects of telmisartan on lipid and glucose metabolism and losartan's effects of lowering uric acid levels. Such effects might lead to new indications for these drugs but further research is needed.